News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

OncoSec Medical Inc. Presents New Data At 10th Annual PEGS: The Essential Protein Engineering Summit In Boston



5/5/2014 7:10:59 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, today presented preliminary experimental findings demonstrating that electroporation with DNA-based IL-12 in mice can lead to systemic anti-tumor immune responses in distant untreated lesions. These data are consistent with the previously reported findings in melanoma patients treated in the Phase 2 OMSI100 study (December 2013).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES